GlycoMimetics Stock (NASDAQ:GLYC)


Chart

Previous Close

$15.90

52W Range

$0.15 - $63.00

50D Avg

$22.49

200D Avg

$24.90

Market Cap

$1.05B

Avg Vol (3M)

$19.73K

Beta

1.60

Div Yield

-

GLYC Company Profile


GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

4

IPO Date

Jan 10, 2014

Website

GLYC Performance


Latest Earnings Call Transcripts


Q2 22Aug 03, 22 | 4:08 PM
Q1 22Apr 30, 22 | 4:52 PM
Q4 21Mar 03, 22 | 11:47 AM

Peer Comparison


TickerCompany
CDTXCidara Therapeutics, Inc.
APLTApplied Therapeutics, Inc.
MGNXMacroGenics, Inc.
CTMXCytomX Therapeutics, Inc.
GLMDGalmed Pharmaceuticals Ltd.